This site is intended for U.S. healthcare professionals.

DANYELZA® (naxitamab-gqgk) 40mg/10mL Injection Administration and Management of Adverse Reactions

Y-mAbs Learning Program
DANYELZA® (naxitamab-gqgk) 40mg/10mL Injection Administration and Management of Adverse Reactions
DANYELZA® (naxitamab-gqgk) 40mg/10mL Injection Administration and Management of Adverse Reactions
April 30, 2020 root
Current Status
Not Enrolled
Price
Free
Get Started
Login to Enroll

DANYELZA® (naxitamab-gqgk) 40mg/10mL Injection Administration and Management of Adverse Reactions

This module will delve into the process of DANYELZA® administration and management of adverse reactions. You will learn key aspects of preparing the patient to receive the infusion, premedication orders, and important strategies for handling pain and any adverse reactions.

Please see Important Safety Information including Boxed Warning on serious infusion-related reactions and neurotoxicity.

DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutic, Inc.

Course Content

Categories:Uncategorized
0 Likes

Indication
 
DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
 
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).